HK1035205A1 - Recombinant adeno-associated viral vector encodingalpha-1-antitrypsin for gene therapy. - Google Patents
Recombinant adeno-associated viral vector encodingalpha-1-antitrypsin for gene therapy.Info
- Publication number
- HK1035205A1 HK1035205A1 HK01103975A HK01103975A HK1035205A1 HK 1035205 A1 HK1035205 A1 HK 1035205A1 HK 01103975 A HK01103975 A HK 01103975A HK 01103975 A HK01103975 A HK 01103975A HK 1035205 A1 HK1035205 A1 HK 1035205A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- gene therapy
- methods
- antitrypsin
- encodingalpha
- viral vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8302598P | 1998-04-24 | 1998-04-24 | |
PCT/US1999/008921 WO1999055564A2 (en) | 1998-04-24 | 1999-04-23 | Materials and methods for gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1035205A1 true HK1035205A1 (en) | 2001-11-16 |
Family
ID=22175690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK01103975A HK1035205A1 (en) | 1998-04-24 | 2001-06-11 | Recombinant adeno-associated viral vector encodingalpha-1-antitrypsin for gene therapy. |
Country Status (11)
Country | Link |
---|---|
US (4) | US6461606B1 (de) |
EP (1) | EP1071806B1 (de) |
AT (1) | ATE269412T1 (de) |
AU (1) | AU3663699A (de) |
CA (1) | CA2326327C (de) |
DE (1) | DE69918090T2 (de) |
DK (1) | DK1071806T3 (de) |
ES (1) | ES2219011T3 (de) |
HK (1) | HK1035205A1 (de) |
NZ (1) | NZ507308A (de) |
PT (1) | PT1071806E (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6759237B1 (en) * | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
US6821775B1 (en) * | 2000-02-11 | 2004-11-23 | Genvec, Inc. | Viral vector encoding pigment epithelium-derived factor |
JP4744771B2 (ja) | 2000-05-26 | 2011-08-10 | 大日本住友製薬株式会社 | 副作用を軽減した新規な組換えアデノウイルスベクター |
CA2448120A1 (en) * | 2001-05-24 | 2002-11-28 | Genzyme Corporation | Muscle-specific expression vectors |
US7312202B2 (en) * | 2003-02-18 | 2007-12-25 | Board Of Regents, The University Of Texas System | Rationally designed and chemically synthesized promoter for genetic vaccine and gene therapy |
ES2247942B1 (es) * | 2004-08-27 | 2006-10-01 | Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria (Inia) | Construccion genica, vector y vacuna adn para la vacunacion de animales acuaticos. |
US7479550B2 (en) * | 2006-06-02 | 2009-01-20 | The Board Of Regents Of The University Of Texas System | Amyloid β gene vaccines |
AU2009206089B2 (en) | 2008-01-15 | 2014-08-28 | Abbvie Inc. | Improved mammalian expression vectors and uses thereof |
AU2012327236B2 (en) | 2011-10-28 | 2016-11-10 | University Of Florida Research Foundation, Inc. | Chimeric promoter for cone photoreceptor targeted gene therapy |
EP3381461B1 (de) | 2012-01-09 | 2021-03-10 | Serpin Pharma, LLC | Peptide und verfahren zur verwendung davon |
PL3253406T3 (pl) | 2015-02-05 | 2024-04-29 | Canem Holdings, Llc | Kompozycje do leczenia ziarniniakowatości z zapaleniem naczyń |
MX2017011255A (es) | 2015-03-03 | 2018-08-01 | Fond Telethon | Sistema de vector múltiple y sus usos. |
JP6929272B2 (ja) | 2015-08-28 | 2021-09-01 | セルピン ファーマ リミテッド ライアビリティ カンパニー | 疾患処置のための方法 |
EP3356397A1 (de) | 2015-09-28 | 2018-08-08 | Fondazione Telethon | Behandlung von knochenwachstumsstörungen |
FI3723790T3 (fi) * | 2017-12-12 | 2024-04-19 | Kamada Ltd | Menetelmiä immuunitoleranssin indusoimiseksi ja lääkevasta-ainevasteen vähentämiseksi |
CA3142948A1 (en) * | 2019-02-15 | 2020-08-20 | Allen Institute | Artificial expression constructs for selectively modulating gene expression in selected neuronal cell populations |
CN115484975A (zh) * | 2020-04-06 | 2022-12-16 | 同源药物公司 | 用于ids基因转移的腺相关病毒组合物和其使用方法 |
WO2023213817A1 (en) | 2022-05-02 | 2023-11-09 | Fondazione Telethon Ets | Gene therapy for gyrate atrophy of the choroid and retina |
CN117223676A (zh) * | 2023-09-25 | 2023-12-15 | 武汉大学 | 面中部发育畸形动物选育方法、辅助选育试剂和预防药物 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US6261834B1 (en) * | 1991-11-08 | 2001-07-17 | Research Corporation Technologies, Inc. | Vector for gene therapy |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
US5439824A (en) * | 1993-05-06 | 1995-08-08 | The United States Of America | Increased expression of α-1-antitrypsin in expression vectors through the inclusion of intron II |
DE69433592T2 (de) | 1993-11-09 | 2005-02-10 | Targeted Genetics Corp., Seattle | Die erzielung hoher titer des rekombinanten aav-vektors |
US5693531A (en) * | 1993-11-24 | 1997-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vector systems for the generation of adeno-associated virus particles |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US6204059B1 (en) * | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US5652224A (en) * | 1995-02-24 | 1997-07-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism |
US5846528A (en) | 1996-01-18 | 1998-12-08 | Avigen, Inc. | Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence |
US5858351A (en) | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
US6723707B1 (en) * | 1997-08-25 | 2004-04-20 | The Trustees Of The University Of Pennsylvania | Use of insulin-like growth factor-I in muscle |
-
1999
- 1999-04-23 DK DK99918810T patent/DK1071806T3/da active
- 1999-04-23 AT AT99918810T patent/ATE269412T1/de active
- 1999-04-23 DE DE69918090T patent/DE69918090T2/de not_active Expired - Lifetime
- 1999-04-23 NZ NZ507308A patent/NZ507308A/xx not_active IP Right Cessation
- 1999-04-23 ES ES99918810T patent/ES2219011T3/es not_active Expired - Lifetime
- 1999-04-23 AU AU36636/99A patent/AU3663699A/en not_active Abandoned
- 1999-04-23 CA CA002326327A patent/CA2326327C/en not_active Expired - Fee Related
- 1999-04-23 PT PT99918810T patent/PT1071806E/pt unknown
- 1999-04-23 US US09/299,141 patent/US6461606B1/en not_active Expired - Lifetime
- 1999-04-23 EP EP99918810A patent/EP1071806B1/de not_active Expired - Lifetime
-
2001
- 2001-06-11 HK HK01103975A patent/HK1035205A1/xx not_active IP Right Cessation
-
2002
- 2002-10-08 US US10/267,117 patent/US20030082162A1/en not_active Abandoned
-
2003
- 2003-01-10 US US10/340,112 patent/US20030095949A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/932,912 patent/US20090186002A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2326327C (en) | 2009-06-16 |
US20030095949A1 (en) | 2003-05-22 |
US20030082162A1 (en) | 2003-05-01 |
NZ507308A (en) | 2003-01-31 |
AU3663699A (en) | 1999-11-16 |
DK1071806T3 (da) | 2004-07-19 |
DE69918090T2 (de) | 2005-06-16 |
EP1071806A2 (de) | 2001-01-31 |
ATE269412T1 (de) | 2004-07-15 |
ES2219011T3 (es) | 2004-11-16 |
US20090186002A1 (en) | 2009-07-23 |
WO1999055564A1 (en) | 1999-11-04 |
WO1999055564A9 (en) | 2000-04-06 |
PT1071806E (pt) | 2004-09-30 |
DE69918090D1 (de) | 2004-07-22 |
US6461606B1 (en) | 2002-10-08 |
WO1999055564A8 (en) | 1999-12-02 |
EP1071806B1 (de) | 2004-06-16 |
CA2326327A1 (en) | 1999-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1035205A1 (en) | Recombinant adeno-associated viral vector encodingalpha-1-antitrypsin for gene therapy. | |
NO954466L (no) | Adenovirale vektorer av animalsk opprinnelse samt deres anvendelse i genterapi | |
ATE330019T1 (de) | Vektor zur gewebespezifischen replikation und expression | |
DE69535703D1 (de) | Aav-vermittelte überbringung von dna in zellen des nervensystems | |
FI951404A0 (fi) | Adenovirusvektoreita vieraiden geenien siirtämiseksi keskushermostojärjestelmän, erityisesti aivojen, soluihin | |
MY132189A (en) | Recombinant obese (ob) proteins | |
ATE304058T1 (de) | Rekombinante mva viren und deren verwendung | |
DE69534791D1 (de) | Vektoren zur gewebsspezifischen replikation | |
DE69703689T2 (de) | Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia | |
WO2002044320A3 (en) | Human elongase genes and uses thereof | |
WO1998048027A3 (en) | Materials and methods for treatment of retinal diseases | |
MXPA05008704A (es) | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. | |
ATE324442T1 (de) | Varianten des p53-proteins und deren therapeutischen verwendungen | |
WO2000009754A3 (en) | HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS | |
ATE433461T1 (de) | Rana pipiens proteine und deren verwendung in der behandlung von tumoren | |
AP2000001999A0 (en) | Gene therapy method. | |
ATE287722T1 (de) | Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1 | |
DE60315628D1 (de) | Modifizierte cea nucleinsäure und expressionsvektoren | |
EP0707655A1 (de) | Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen | |
ATE292177T1 (de) | Gentherapy von lungenkrankheiten | |
NO964894L (no) | Rekombinante viruser, deres fremstilling samt anvendelse av genterapi | |
WO2002044357A3 (en) | Methods of using 18903 to treat pain and pain-related disorders | |
MX9707549A (es) | Vectores virales y su uso para tratar trastornos hiperproliferativos, en particular restenosis. | |
WO2003027316A3 (en) | Methods of using 33751, a human potassium channel family member |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AM | Amended specification (according sect 146 of patent law) |
Free format text: CORRECTION OF THE NAME OF INVENTOR FROM BARRY J. BYRNES TO BARRY J. BYRNE. Effective date: 20050304 |
|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170423 |